CAMP4 Therapeutics Corporation (CAMP)

US — Healthcare Sector
Peers: KVHI  AIOT  CMTL  DZSI  HLIT  ADTN  AMBA  DGII 

Automate Your Wheel Strategy on CAMP

With Tiblio's Option Bot, you can configure your own wheel strategy including CAMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CAMP
  • Rev/Share 0.1492
  • Book/Share 1.9835
  • PB 1.7393
  • Debt/Equity 0.1782
  • CurrentRatio 5.6014
  • ROIC -1.0675

 

  • MktCap 69555702.0
  • FreeCF/Share -2.2893
  • PFCF -1.5071
  • PE -1.3431
  • Debt/Assets 0.1389
  • DivYield 0
  • ROE -1.312

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CAMP Cantor Fitzgerald -- Overweight -- $7 Oct. 2, 2025
Downgrade CAMP JP Morgan Overweight Neutral -- -- Sept. 16, 2025
Initiation CAMP Wedbush -- Outperform -- $8 May 27, 2025

News

CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
CAMP
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive

CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
CAMP
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes

Read More
image for news CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
CAMP
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108

Read More
image for news CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

About CAMP4 Therapeutics Corporation (CAMP)

  • IPO Date 2024-10-11
  • Website https://www.camp4tx.com
  • Industry Biotechnology
  • CEO Joshua Mandel-Brehm
  • Employees 55
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.